Stockscreener 앱 받기
2.58
0.39%
0.01
시간 외 거래:
2.56
-0.02
-0.78%
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics (RPTX) Shareholders Approve Acquisition by X - GuruFocus
Repare Therapeutics Shareholders Approve Acquisition by XenoTherapeutics - TipRanks
Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - marketscreener.com
Bank Watch: Is Repare Therapeutics Inc stock heavily shorted2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update - MarketBeat
Update Report: Is Repare Therapeutics Inc stock heavily shorted2025 Market Trends & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Repare Therapeutics (NASDAQ:RPTX) Stock Price Up 0.4%Here's Why - MarketBeat
Levels Update: Is Repare Therapeutics Inc. stock a top pick in earnings season2025 Sector Review & Daily Stock Trend Watchlist - Bộ Nội Vụ
Aug Opening: Will Repare Therapeutics Inc stock attract ESG investorsMarket Sentiment Summary & AI Driven Stock Price Forecasts - Bộ Nội Vụ
Insider Trends: Why Repare Therapeutics Inc. stock is in analyst buy zonePortfolio Update Report & Capital Efficient Trading Techniques - Bộ Nội Vụ
Published on: 2026-01-13 02:16:07 - baoquankhu1.vn
What catalysts could drive Repare Therapeutics Inc. stock higherTrade Exit Summary & Smart Investment Allocation Tips - Улправда
Oklahoma City NewsThe OklahomanRepare Therapeutics Inc.Common Shares (Nasdaq:RPTX) Stock Quote - FinancialContent
Is Repare Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Review & Risk Managed Trade Strategies - Улправда
Can Repare Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда
Will Repare Therapeutics Inc. stock benefit from commodity prices2025 Big Picture & Momentum Based Trading Signals - ulpravda.ru
Repare Therapeutics sells RP-3467 cancer program assets to Gilead for up to $30 million - MSN
Can Repare Therapeutics Inc. stock double in next 5 yearsVolatility Adjusted Trading & Learn to Trade with Real-Time Feedback - Улправда
Repare Therapeutics Inc.Common Shares (NQ: RPTX - FinancialContent
Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million - TipRanks
Repare Therapeutics Announces Gilead Acquisition of RP-3467 for Up to $30 Million - citybiz
PYXS,RPTX Dividends - Finviz
Repare Therapeutics announces CSO resignation and transition plan - MSN
Repare Therapeutics Sells RP-3467 Program to Gilead - The Globe and Mail
Aug Drivers: How buybacks impact Repare Therapeutics Inc stock valueMarket Movement Recap & Weekly High Return Stock Forecasts - moha.gov.vn
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com Nigeria
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Black Hills Pioneer
Repare Sells Key Oncology Asset to Gilead, Lifts Expected Xeno Deal Payout - TipRanks
RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug - MSN
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Nigeria
Repare’s Sale Sparks Concerns: Time to Sell? - StocksToTrade
Repare Therapeutics Sees Unusually Large Options Volume (NASDAQ:RPTX) - MarketBeat
Gilead Sciences Acquires Polθ ATPase Inhibitor RP-3467 for $30 Million - El-Balad.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Repare Therapeutics Faces Scrutiny Amid Sale Deal - timothysykes.com
Repare Therapeutics (RPTX) Surges on $30M Asset Sale to Gilead - GuruFocus
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Sells Polymerase Theta ATPase Inhibitor To Gilead For Up To $30Mln - Nasdaq
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):